SG11201811258UA - Process for the production of a dna vaccine for cancer immunotherapy - Google Patents
Process for the production of a dna vaccine for cancer immunotherapyInfo
- Publication number
- SG11201811258UA SG11201811258UA SG11201811258UA SG11201811258UA SG11201811258UA SG 11201811258U A SG11201811258U A SG 11201811258UA SG 11201811258U A SG11201811258U A SG 11201811258UA SG 11201811258U A SG11201811258U A SG 11201811258UA SG 11201811258U A SG11201811258U A SG 11201811258UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- dna vaccine
- pct
- transformed cell
- cancer immunotherapy
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 abstract 2
- 108010041986 DNA Vaccines Proteins 0.000 abstract 2
- 229940021995 DNA vaccine Drugs 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 January 2018 (18.01.2018) W I PO I PCT onion °nolo III m OH Oil OH oimIE (10) International Publication Number WO 2018/011289 Al (51) International Patent Classification: A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2017/067590 (22) International Filing Date: 12 July 2017 (12.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16001550.9 13 July 2016 (13.07.2016) EP (71) Applicant: VAXIMM AG [CH/CH]; Hochbergstrasse 60c, 4057 Basel (CH). (72) Inventor: LUBENAU, Heinz; An der Eselshaut 12, 67435 Neustadt an der Weinstrasse (DE). (74) Agent: WALLINGER RICKER SCHLOTTER TOST- MANN; Mathias Ricker, Patent- and Rechtsanwalte Part- nerschaft mbB, ZweibriickenstraBe 5-7, 80331 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) 1-1 with sequence listing part of description (Rule 5.2(a)) QC (54) Title: PROCESS FOR THE PRODUCTION OF A DNA VACCINE FOR CANCER IMMUNOTHERAPY 1-1 (57) : The present invention relates to a method for producing a DNA vaccine for cancer immunotherapy comprising at least the steps of (a) transforming an attenuated strain of Salmonella with at least one DNA molecule comprising at least one expression cassette encoding at least one antigen or at least one fragment thereof; (b) characterizing at least one transformed cell clone obtained in step (a); and (c) selecting at least one of the transformed cell clone(s) characterized in step (b) and further characterizing said at 1-1 © least one selected transformed cell clone. The present invention further relates to a DNA vaccine obtainable by the method according f'1 to the present invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811258UA true SG11201811258UA (en) | 2019-01-30 |
Family
ID=56418345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811258UA SG11201811258UA (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (en) |
| EP (1) | EP3484503A1 (en) |
| JP (2) | JP7098599B2 (en) |
| KR (2) | KR20230079514A (en) |
| CN (1) | CN109475614A (en) |
| AU (1) | AU2017295004B2 (en) |
| BR (1) | BR112019000657A2 (en) |
| CA (1) | CA3028549A1 (en) |
| IL (1) | IL263568A (en) |
| MX (1) | MX2019000415A (en) |
| RU (1) | RU2019100079A (en) |
| SG (1) | SG11201811258UA (en) |
| WO (1) | WO2018011289A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019009724A (en) * | 2017-02-17 | 2019-10-07 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach. |
| CA3069523A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| KR20210030973A (en) | 2018-07-11 | 2021-03-18 | 액팀 테라퓨틱스, 인코퍼레이티드 | Engineered immunostimulatory bacterial strains and uses thereof |
| JP2021536247A (en) * | 2018-09-05 | 2021-12-27 | バクシム アクチェンゲゼルシャフト | Neoantigen targeting DNA vaccines for combination therapy |
| EP4090321A1 (en) | 2020-01-13 | 2022-11-23 | Vaximm AG | Salmonella-based dna vaccines in combination with an antibiotic |
| WO2024005122A1 (en) * | 2022-06-30 | 2024-01-04 | 株式会社島津製作所 | Method for preparing analysis of microorganisms, and method for analyzing microorganisms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2836494C (en) * | 2011-05-24 | 2023-01-03 | Biontech Ag | Individualized vaccines for cancer |
| US9493738B2 (en) * | 2011-12-22 | 2016-11-15 | Vaximm Ag | Method for producing high yield attenuated Salmonella strains |
| EP3603664A1 (en) * | 2012-07-05 | 2020-02-05 | Vaximm AG | Dna vaccine for use in pancreatic cancer patients |
| PL2988762T3 (en) | 2013-04-25 | 2019-01-31 | Vaximm Ag | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
| CN106061500A (en) * | 2013-12-18 | 2016-10-26 | 万科斯蒙股份有限公司 | Novel MSLN targeting dna vaccine for cancer immunotherapy |
| WO2015095811A2 (en) * | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
-
2017
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/en not_active Application Discontinuation
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/en not_active Application Discontinuation
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/en not_active Application Discontinuation
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/en unknown
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en unknown
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/en active Pending
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/en not_active IP Right Cessation
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/en active Active
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7098599B2 (en) | 2022-07-11 |
| US20220072112A1 (en) | 2022-03-10 |
| MX2019000415A (en) | 2019-03-28 |
| JP2022097591A (en) | 2022-06-30 |
| US11590215B2 (en) | 2023-02-28 |
| RU2019100079A (en) | 2020-08-13 |
| CA3028549A1 (en) | 2018-01-18 |
| US10821163B2 (en) | 2020-11-03 |
| KR20230079514A (en) | 2023-06-07 |
| WO2018011289A1 (en) | 2018-01-18 |
| CN109475614A (en) | 2019-03-15 |
| EP3484503A1 (en) | 2019-05-22 |
| US20190183996A1 (en) | 2019-06-20 |
| AU2017295004A1 (en) | 2019-01-03 |
| BR112019000657A2 (en) | 2019-04-24 |
| JP2019521154A (en) | 2019-07-25 |
| AU2017295004B2 (en) | 2020-08-13 |
| KR20190027834A (en) | 2019-03-15 |
| IL263568A (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811258UA (en) | Process for the production of a dna vaccine for cancer immunotherapy | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201900468YA (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| SG11201909154SA (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201810149VA (en) | Anti hla-g specific antibodies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201808476SA (en) | Recycling of polymer matrix composite | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201807636XA (en) | Process for producing a polyacrylamide solution with increased viscosity | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201907319QA (en) | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers |